Skip to main content

Table 2 Summary of MTX use between weeks 0 and 52 in patients with stable MTX dose

From: Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

 

SPIRIT-P1 and SPIRIT-P2

IXE Q4W (N = 229)

IXE Q2W (N = 226)

Patients with stable MTX dose, n (%)

85 (37.1)

98 (43.4)

Overall average dose, mg/week

15.7

16.0

Route of MTX administration:

 Intramuscular, n (%)

1 (1.2)

2 (2.0)

 Average dose, mg/week

25.0

12.5

 Subcutaneous, n (%)

14 (16.5)

15 (15.3)

 Average dose, mg/week

17.7

19.7

 Oral, n (%)

70 (82.4)

81 (82.7)

 Average dose, mg/week

15.2

15.4

  1. Abbreviations: IXE Q2W 80 mg ixekizumab every 2 weeks, IXE Q4W 80 mg ixekizumab every 4 weeks, MTX methotrexate, N number of patients in each group, n number of patients in specific group